FDA Investigator Dandan Wang, PhD
Dandan Wang, PhD has conducted inspections on 14 sites in 6 countries as of 28 Jul 2019. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
14
Last Inspection Date:
28 Jul 2019
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
New Zealand,
Taiwan,
China,
Australia,
Israel
FDA Investigators that have inspected at least one site in common with Dandan Wang, PhD:
Ademola O Daramola,
Amanda L Fyles,
Ana Delp Cintron,
Ana P Barido,
Anastasia M Shields,
Andrew Le,
Anh M Lac,
Anita Narula, PhD,
Anita R Michael,
April L Young,
Ashar P Parikh,
Azza Talaat,
Barbara Janine Breithaupt,
Bo Chi, PhD,
Carl A Huffman, III,
Carol A Gripp,
Caryn M Mcnab,
CDR Ileana Barreto Pettit,
Chiaochun J Wang,
Christina K Theodorou,
Christopher R Czajka,
Connie P Rezendes,
Craig A Garmendia,
Cynthia J Lee, MS,
Daniel J Roberts,
Darren S Brown,
David J Daworski,
Dawn M Mccabe,
Denise M Digiulio,
Dennis Cantellops Paite,
Diane T Wade, MS,
Don H Bark, PhD,
Donald B Mckechnie,
Dr. Chunchang Fang,
Dyvette Arline,
Edwin Melendez,
Emest F Bizjak,
Eric L Dong, BS,
Fabian Nchaparro Rodriguez,
Gerard Pde Leon,
Heika R Tait,
Iraida Ortiz,
James S Stuart, BS,
Jeffrey M Watson,
Jen Sui,
Jennifer D Hollstrom,
Jennifer L Huntington,
Jennifer M Menendez,
Jessica L Pressley,
Joanne E King,
Joanne Hosting,
Joey V Quitania,
Jogy George,
John A Gonzalez,
Jonathan W Chapman,
Jose A Lopez,
Juanita P Versace,
Julianne C Mccullough,
Junho Pak,
Justin A Boyd,
Karen A Briggs,
Katherine Szestypalow,
Kelsey M Bishop,
Kenneth M Gordon,
Kenneth O Gee, PhD,
Kevin A Gonzalez,
Kevin P Foley,
Lance Mde Souza, MBA,
Lance W Bohm,
Larry K Austin,
Lawrence Y Lee, PhD,
Leonard H Lavi,
Libia M Lugo,
Linda Thai,
Lisa B Orr,
Lisa K Capron,
Lynda L Perry, PhD,
Margaret M Annes,
Maria A Reed,
Maria Pkelly Doggett, MBA,
Maria V Price,
Marianela Aponte Cruz,
Marie B Buen Bigornia,
Marie F Morin,
Marijo B Kambere, PhD,
Matthew B Casale,
Matthew M Schuckmann,
Maxine H Wong,
Meisha R Sampson,
Meisha Waters,
Michael A Charles,
Michael A Taylor,
Michael S Araneta,
Michele L Obert,
Michelle Yclark Stuart,
Miguel A Martinez Perez,
Mikel T Wright,
Nancy A Saxenian Emmons,
Nancy G Schmidt,
Noreen Muñiz,
Peter C Chow,
Qin Xu,
Rafael E Arroyo,
Randy L Self,
Raymond T Oji,
Rebecca Rodriguez,
Rita K Kabaso,
Robert D Tollefsen,
Robert J Doyle,
Rochelle K Kimmel,
Roger F Zabinski,
Roy R Rinc,
Ruben C Ayala, PharmD,
Rumany C Penn, PharmD,
Sangeeta M Khurana, PhD,
Sarah E Mcmullen,
Satheesh Thomas,
Scott A Nabe,
Scott T Ballard,
Sean R Marcsisin,
Seneca D Toms,
Sharon K Thoma, PharmD,
Shuen G Chai,
Simone E Pitts,
Stephanie A Slater, MS,
Stephanie D Crockett,
Stephen D Brown,
Steven M Weinman,
Sunitha K Rajaram, PhD,
Susan F Laska, MS,
Susan M Corrales,
Susan M Turcovski,
Susanna E Ford,
Ted L Anderson,
Terri L Dodds,
Thomas E Friel,
Thomas J Arista,
Torrance J Slayton,
Tracy K Li,
Uttaniti Limchumroon (Tom),
Viviana Matta,
Vlada Matusovsky,
William C Hughes,
William V Millar
Dandan Wang, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| August, 2013 | FDA 483 | Nang Kuang Pharmaceutical Co. Ltd. - Form 483, 2013-08-30 |
| April, 2019 | FDA 483 Response | APOZEAL PHARMACEUTICALS INC - Form 483R, 2019-04-30 |
| May, 2013 | FDA 483 | Partner Therapeutics, Inc. - Form 483, 2013-05-24 |
| April, 2019 | FDA 483 | APOZEAL PHARMACEUTICALS INC - Form 483, 2019-04-09 |
| July, 2019 | FDA 483 | Teva Pharmaceutical Industries Ltd. - Form 483, 2019-07-25 |
| December, 2009 | FDA 483 | Emerald Kalama Chemical, LLC - Form 483, 2009-12-17 |
| December, 2013 | EIR | Actavis Laboratories FL, Inc. - EIR, 2013-12-20 |
| August, 2019 | FDA 483 | Teva Pharmaceutical Industries Ltd. - Form 483, 2019-08-01 |
| December, 2013 | FDA 483 | Actavis Laboratories FL, Inc. - Form 483, 2013-12-20 |
| December, 2012 | FDA 483 | Cardinal Health 414, LLC - Form 483, 2012-12-14 |
| May, 2013 | EIR | Partner Therapeutics, Inc. - EIR, 2013-05-24 |
| April, 2012 | FDA 483 | AMPAC Fine Chemicals LLC - Form 483, 2012-04-20 |
| December, 2009 | EIR | Emerald Kalama Chemical, LLC - EIR, 2010-02-23 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more